CD8A and neoplasm: Systemic exposure to nanoparticles enabled transient immune recognition of tumor, increased the number of immune cells, such as NK cells, monocytes, CD4+ T cells, and CD8+ T cells, reconfigured TME immune system and delayed tumor growth; Of note, all of these changes were independent of antibody therapeutic activity and therapeutic payload (84).